Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]

Factors influencing response to blinatumomab in relapsed/refractory ALL

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

$Factors influencing response to blinatumomab in relapsed/refractory ALL ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )$

Evidence for kinase inhibitor activity in acute myeloid leukaemia

Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany

Evidence for kinase inhibitor activity in acute myeloid leukaemia ( Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany )

Targeted combination therapy with potential to eliminate relapsed chronic...

Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia

Targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia ( Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia )

New targeted combination therapy with potential to eliminate relapsed chronic...

Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia

New targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia ( Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia )

First randomised evidence for kinase inhibitor activity in acute myeloid...

Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany

First randomised evidence for kinase inhibitor activity in acute myeloid leukaemia ( Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany )

Does the patient with myelofibrosis feel better through pacritinib?

Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA

Does the patient with myelofibrosis feel better through pacritinib? ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )

Adding elotuzumab to standard treatment for multiple myeloma significantly...

Dr Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens...

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression ( Dr Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )

Treatment and survival of patients with chronic myeloid leukaemia in Europe

Dr Verena Hoffmann - Ludwig-Maximilians-Universität, München, Germany

Treatment and survival of patients with chronic myeloid leukaemia in Europe ( Dr Verena Hoffmann - Ludwig-Maximilians-Universität, München, Germany )

PM1183 plus doxorubicin shows interesting activity in small cell lung cancer

Dr Emiliano Calvo - START Madrid, Madrid, Spain

PM1183 plus doxorubicin shows interesting activity in small cell lung cancer ( Dr Emiliano Calvo - START Madrid, Madrid, Spain )

Lenvatinib increases progression free survival when used with everolimus in...

Dr James Larkin - Royal Marsden Hospital, London, UK

Lenvatinib increases progression free survival when used with everolimus in metastatic renal cell carcinoma ( Dr James Larkin - Royal Marsden Hospital, London, UK )

Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer

Dr Simon Chowdhury - Guy's Hospital, London, UK

Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer ( Dr Simon Chowdhury - Guy's Hospital, London, UK )

Screening to identify unsuitable candidates for ipilimumab in advanced melanoma

Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy

Screening to identify unsuitable candidates for ipilimumab in advanced melanoma ( Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy )

More from ecancer